What the Novavax results mean for the UK’s vaccine rollout
Expected approval of the new jab would leave UK with tens of millions of excess doses
Britain’s Covid vaccines rollout is on course to get a fresh boost after a new jab was found to be 89.3% effective in large-scale UK trials.
The UK has already secured 60 million doses of the Novavax vaccine, which will now be assessed by the Medicines and Healthcare products Regulatory Agency and could be “delivered in the second half of this year” if approved, the BBC reports.
Stan Erck, chief executive of Novavax, said the results from the UK phase three trial were “spectacular” and “as good as we could have hoped”.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
How does it work?
The Novavax vaccine “works in a slightly different way to the ones that are already available”, writes BBC health editor Michelle Roberts, “but does the same job of teaching the body's immune system to recognise and fight the pandemic virus”.
To develop the jab, researchers placed “a modified gene into a virus, called a baculovirus, and allowed it to infect insect cells”, ITV reports. Spike proteins from these cells were then “assembled into nanoparticles”, which “while they look like coronavirus, cannot replicate or cause Covid-19”, the broadcaster continues.
These nanoparticles “are then injected into the body via the vaccine where the immune system mounts an antibody response” that helps to protect the patient against future Covid-19 infection.
As the BBC's Williams adds, the Novavax jab also “appears to be effective against emerging and more infectious variants of coronavirus”, including the South African version - a result that scientists had feared “might not be possible because the vaccines were all designed to match the original virus”.
What does it mean for the UK?
If approved, Novavax will be the fourth coronavirus vaccination to get the green light for use in the UK.
And having ordered tens of millions of doses of the jab, along with stocks of “more new vaccines coming down the tracks”, Britain could be left in the “promising position” of possessing “more doses than it needs to vaccinate the entire population”, says Politico's London Playbook.
The promising trial results for Novavax - which would be manufactured in Stockton-on-Tees - have been welcomed by the government.
Health Secretary Matt Hancock said that the “NHS stands ready to roll this vaccine out as quickly as possible to those most at risk if it is authorised”.
Meanwhile, Boris Johnson welcomed the “good news” in a tweet in which the prime minister also thanked “all the volunteers who made these results possible”.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Chas Newkey-Burden has been part of The Week Digital team for more than a decade and a journalist for 25 years, starting out on the irreverent football weekly 90 Minutes, before moving to lifestyle magazines Loaded and Attitude. He was a columnist for The Big Issue and landed a world exclusive with David Beckham that became the weekly magazine’s bestselling issue. He now writes regularly for The Guardian, The Telegraph, The Independent, Metro, FourFourTwo and the i new site. He is also the author of a number of non-fiction books.
-
'Good riddance to the televised presidential debate'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
Caitlin Clark the No. 1 pick in bullish WNBA Draft
Speed Read As expected, she went to the Indiana Fever
By Peter Weber, The Week US Published
-
Today's political cartoons - April 16, 2024
Cartoons Tuesday's cartoons - sleepyhead, little people, and more
By The Week US Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
How happy is Finland really?
Today's Big Question Nordic nation tops global happiness survey for seventh year in a row with 'focus on contentment over joy'
By Harriet Marsden, The Week UK Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Does declining birth rate spell doom for Britain?
Today's Big Question Ageing population puts pressure on welfare state, economy and fabric of society, while fertility is rising on populist agendas
By Harriet Marsden, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published
-
Covid inquiry: the most important questions for Boris Johnson
Talking Point Former PM has faced weeks of heavy criticism from former colleagues at the public hearing
By The Week Staff Published